Klaus Brandenburg Selected Research

Anti-Bacterial Agents (Antibiotics)

10/2023	A Comparison between SARS-CoV-2 and Gram-Negative Bacteria-Induced Hyperinflammation and Sepsis.
11/2022	Repurposing the Antibacterial Agents Peptide 19-4LF and Peptide 19-2.5 for Treatment of Cutaneous Leishmaniasis.
3/2021	Encapsulation and release of As pidasept peptides in polysaccharide formulation for oral application.
2/2021	Anti-Infective and Anti-Inflammatory Mode of Action of Peptide 19-2.5.
1/2021	An update on endotoxin neutralization strategies in Gram-negative bacterial infections.
11/2020	Fatty Acid Conjugation Leads to Length-Dependent Antimicrobial Activity of a Synthetic Antibacterial Peptide (Pep19-4LF).
1/2019	Antibacterial action of synthetic antilipopolysaccharide peptides (SALP) involves neutralization of both membrane-bound and free toxins.
1/2018	Antimicrobial Peptides and Their Therapeutic Potential for Bacterial Skin Infections and Wounds.
1/2017	Coupling killing to neutralization: combined therapy with ceftriaxone/Pep19-2.5 counteracts sepsis in rabbits.
8/2015	Lack of new antiinfective agents: Passing into the pre-antibiotic age?

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Klaus Brandenburg Research Topics

Disease

30	Sepsis (Septicemia) 10/2023 - 01/2006
17	Infections 02/2022 - 01/2007
15	Septic Shock (Toxic Shock Syndrome) 12/2022 - 10/2004
14	Inflammation (Inflammations) 10/2023 - 06/2009
11	Bacterial Infections (Bacterial Infection) 12/2022 - 10/2007
3	Bacteremia 03/2021 - 03/2013
3	Endotoxemia 03/2021 - 03/2013
3	Shock 01/2018 - 09/2010
3	Wounds and Injuries (Trauma) 01/2018 - 01/2018
2	Soft Tissue Infections 12/2022 - 01/2018
2	Gram-Negative Bacterial Infections 01/2021 - 01/2015
2	Multiple Organ Failure (MODS) 01/2018 - 09/2010
2	Necrosis 10/2014 - 09/2007
2	Communicable Diseases (Infectious Diseases) 05/2011 - 10/2008
1	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 10/2023
1	COVID-19 10/2023
1	Cutaneous Leishmaniasis 11/2022
1	Wound Infection (Wound Infections) 03/2021
1	Hypercholesterolemia 01/2021
1	Fatty Liver 01/2021
1	Insulin Resistance 01/2021
1	Obesity 01/2021
1	Proteinuria 01/2021
1	Liver Diseases (Liver Disease) 01/2018
1	Pneumonia (Pneumonitis) 01/2018
1	Hemorrhagic Shock 01/2018
1	Leukopenia 01/2017
1	Hyperlactatemia 01/2017
1	Hypothermia 01/2017
1	Hyperglycemia 01/2017
1	Cardiomyopathies (Cardiomyopathy) 11/2016
1	Mitochondrial Diseases (Mitochondrial Disease) 11/2016
1	Immune System Diseases (Immune Disorders) 09/2016
1	Pain (Aches) 01/2016
1	Tuberculosis (Tuberculoses) 08/2010
1	Plague (Bubonic Plague) 06/2010
1	Meningococcal Infections 01/2007
1	Meningitis 01/2007
1	Melioidosis 03/2006

Drug/Important Bio-Agent (IBA)

24	Peptides (Polypeptides)IBA 12/2022 - 09/2007
23	EndotoxinsIBA 10/2023 - 10/2004
19	LipopolysaccharidesIBA 10/2023 - 10/2004
16	Antimicrobial PeptidesIBA 03/2021 - 10/2007
13	Anti-Bacterial Agents (Antibiotics)IBA 10/2023 - 09/2010
8	Pep19-2.5 peptideIBA 12/2022 - 01/2013
6	Virulence Factors (Pathogenicity Factors)IBA 01/2017 - 09/2007
5	CytokinesIBA 10/2023 - 09/2010
5	Lipoproteins (Lipoprotein)IBA 02/2021 - 09/2015
4	Pep19-4LFIBA 12/2022 - 11/2016
4	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 02/2021 - 06/2009
3	Adenosine Monophosphate (AMP)IBA 03/2021 - 02/2015
3	InflammasomesIBA 01/2021 - 01/2017
3	Proteins (Proteins, Gene)FDA Link 01/2021 - 09/2007
3	Anti-Inflammatory Agents (Anti-Inflammatories)IBA 01/2018 - 01/2015
3	Heparitin Sulfate (Heparan Sulfate)IBA 01/2015 - 06/2012
2	Peptide Hydrolases (Proteases)FDA Link 03/2018 - 06/2010
2	Antimicrobial Cationic PeptidesIBA 01/2018 - 04/2007
2	Toll-Like Receptor 4IBA 01/2017 - 01/2007
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2017 - 03/2006
2	Adenosine Triphosphate (ATP)IBA 01/2017 - 11/2016
2	Local Anti-Infective Agents (Antiseptics)IBA 03/2013 - 09/2010
1	Immunologic Adjuvants (Immunologic Adjuvant)IBA 10/2023
1	Colistin (Coly-Mycin)FDA Link 02/2022
1	Polysaccharides (Glycans)IBA 03/2021
1	Phosphotransferases (Kinase)IBA 01/2021
1	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 01/2021
1	CathelicidinsIBA 01/2018
1	AntitoxinsIBA 01/2018
1	Interleukin-6 (Interleukin 6)IBA 01/2017
1	Ceftriaxone (Ceftriaxon)FDA LinkGeneric 01/2017
1	CaspasesIBA 01/2017
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 11/2016
1	Pattern Recognition ReceptorsIBA 09/2016
1	LigandsIBA 09/2016
1	Ibuprofen (Motrin)FDA LinkGeneric 01/2015
1	heparanaseIBA 01/2015
1	Pathogen-Associated Molecular Pattern MoleculesIBA 01/2015
1	Therapeutic UsesIBA 01/2015
1	Messenger RNA (mRNA)IBA 01/2013
1	salicylhydroxamic acid (SHAM)IBA 01/2013
1	Polymyxin B (Aerosporin)FDA LinkGeneric 01/2013
1	Erythromycin (Erycette)FDA LinkGeneric 01/2011
1	LipopeptidesIBA 08/2010
1	PlasminogenIBA 06/2010
1	Phospholipids (Phosphatides)FDA LinkGeneric 06/2009
1	Lipid AIBA 10/2008
1	endotoxin binding proteinsIBA 10/2007
1	factor AIBA 09/2007
1	antilipopolysaccharide factor (Limulus)IBA 09/2007
1	ExotoxinsIBA 03/2006
1	rhamnolipidIBA 03/2006

Therapy/Procedure

8	Therapeutics 10/2023 - 01/2006
3	Critical Care (Surgical Intensive Care) 05/2016 - 01/2013
2	Punctures 03/2013 - 01/2013
2	Ligation 03/2013 - 01/2013
1	Resuscitation 01/2018
1	Oral Administration 02/2015